A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics

Progression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on...

Full description

Bibliographic Details
Main Authors: Jiajie Yu, Nina Wang, Matts Kågedal
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12499
id doaj-bb192ad3c4384059a862f04a9b70eecf
record_format Article
spelling doaj-bb192ad3c4384059a862f04a9b70eecf2020-11-25T03:35:35ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062020-03-019317718410.1002/psp4.12499A New Method to Model and Predict Progression Free Survival Based on Tumor Growth DynamicsJiajie Yu0Nina Wang1Matts Kågedal2Department of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USADepartment of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USADepartment of Clinical PharmacologyGenentech Research and Early Development South San Francisco California USAProgression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum‐resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.https://doi.org/10.1002/psp4.12499
collection DOAJ
language English
format Article
sources DOAJ
author Jiajie Yu
Nina Wang
Matts Kågedal
spellingShingle Jiajie Yu
Nina Wang
Matts Kågedal
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
CPT: Pharmacometrics & Systems Pharmacology
author_facet Jiajie Yu
Nina Wang
Matts Kågedal
author_sort Jiajie Yu
title A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
title_short A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
title_full A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
title_fullStr A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
title_full_unstemmed A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics
title_sort new method to model and predict progression free survival based on tumor growth dynamics
publisher Wiley
series CPT: Pharmacometrics & Systems Pharmacology
issn 2163-8306
publishDate 2020-03-01
description Progression‐free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum‐resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.
url https://doi.org/10.1002/psp4.12499
work_keys_str_mv AT jiajieyu anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
AT ninawang anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
AT mattskagedal anewmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
AT jiajieyu newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
AT ninawang newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
AT mattskagedal newmethodtomodelandpredictprogressionfreesurvivalbasedontumorgrowthdynamics
_version_ 1724553557723578368